Letter 1: French multicentre prospective observational study of laparoscopicversus open colectomy for sigmoid diverticular disease (Br J Surg 2005; 92: 1520–1525)

2006 ◽  
Vol 93 (4) ◽  
pp. 504-504
Author(s):  
T. Salem
Keyword(s):  
Observational Study ◽  
Diverticular Disease ◽  
Prospective Observational Study ◽  
Open Colectomy ◽  
Sigmoid Diverticular Disease

Laparoscopic Colectomy vs. Open Colectomy For Sigmoid Diverticular Disease

2002 ◽  
Vol 45 (10) ◽  
pp. 1309-1315 ◽  
Author(s):  
Amit Dwivedi ◽  
Fadi Chahin ◽  
Sunita Agrawal ◽  
W. Y. Chau ◽  
A. Tootla ◽  
...  
Keyword(s):  
Diverticular Disease ◽  
Laparoscopic Colectomy ◽  
Open Colectomy ◽  
Sigmoid Diverticular Disease

scholarly journals Efficacy of a New Nutraceutical Formulation in Patients with Symptomatic Uncomplicated Diverticular Disease (SUDD): a Prospective Observational Study

2020 ◽  
Vol 28 ◽  
pp. 49-52
Author(s):  
Ferdinando D'Amico ◽  
Giulia Fiorini ◽  
Antonio Tursi ◽  
Ilaria Maria Saracino ◽  
Matteo Pavoni ◽  
...  
Keyword(s):  
Abdominal Pain ◽  
Adverse Events ◽  
Observational Study ◽  
Diverticular Disease ◽  
Prospective Observational Study ◽  
Remission Rate ◽  
Acute Diverticulitis ◽  
Symptom Relief ◽  
Bowel Habits ◽  
Uncomplicated Diverticular Disease

Background and Aim: Symptomatic uncomplicated diverticular disease (SUDD) is characterized by abdominal pain, bloating and altered bowel habits (constipation or diarrhea) attributed to diverticula in the absence of macroscopic mucosal alterations. There is no consensus about management of these patients. DIVER-100®, an association of natural active ingredients may be effective in the treatment of patients with SUDD. The aim was to evaluate the efficacy and safety of DIVER-100® in patients with SUDD. Methods: We conducted a prospective observational study to evaluate the efficacy of DIVER-100® in consecutive patients with SUDD, confirmed by radiology or endoscopy. All patients were treated with DIVER-100® 2 capsules/day 10 days per month, for 3 months. The primary endpoint was the clinical remission rate, defined as the reduction of abdominal pain and bloating, improvement of bowel habits and prevention of acute diverticulitis (AD). The secondary endpoint was the rate of adverse events. Results: One hundred and one patients were consecutively enrolled at the Internal Medicine and Gastroenterology Unit, Sant’Orsola Hospital, Bologna, Italy. DIVER-100® was effective in inducing remission of symptoms in 12 patients (11.9%) at 3 months and in 10 patients (9.9%) at 6 months. DIVER-100® significantly reduced abdominal pain and bloating in 45.5% and 57.4% of patients respectively (p <0.001) after 3 months. No episodes of AD and no adverse events related to DIVER--100® were recorded at month 6 in the study population. Conclusions: DIVER-100® is a safe and effective nutraceutical compound in obtaining remission and symptom relief in SUDD patients. Further randomized, placebo-controlled clinical trials are needed to confirm these preliminary data.

Prospective Observational Study of Sleep and PTSD Symptoms in Patients Undergoing PTSD Treatment

2009 ◽  
Author(s):  
Ihori Kobayashi ◽  
Brian Hall ◽  
Courtney Hout ◽  
Vanessa Springston ◽  
Patrick Palmieri
Keyword(s):  
Observational Study ◽  
Prospective Observational Study ◽  
Ptsd Symptoms ◽  
Ptsd Treatment

The 1000Plus study protocol – a prospective observational study on the mismatch concept in a 3.0 T MRI

2009 ◽  
Vol 36 (S 02) ◽  
Author(s):  
B Hotter ◽  
S Pittl ◽  
M Ebinger ◽  
G Oepen ◽  
K Jegzentis ◽  
...  
Keyword(s):  
Observational Study ◽  
Study Protocol ◽  
Prospective Observational Study ◽  
3.0 T ◽  
3.0 T Mri
Sign in / Sign up

Export Citation Format

Share Document